| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Dermatologic System | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Dermatologic System | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Dermatologic System |
Recent Updates
Recently added Catalysts
Corvus Pharmaceuticals, Inc.$15.67
-0.53 (-3.27%)
C 48Pipeline Score Fair Value Pharma · Commercial
Market Cap
1.06 B
EPS
-0.53
P/E Ratio
-
Value Trade
18.57 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
11.18 M
Operating CF
-10.37 M
Total Assets
253.19 M
Total Liabilities
12.52 M
Equity
240.68 M
D/E Ratio
12,345
-6.38 %
Week
-29.2 %
1 Month
-27.28 %
3 Month
48.18 %
6 Month
385 %
5 Year
-15.93 %
All Time
Cash Data
Cash Position
236.71 M
Monthly Burn
3.46 M
Runway
66.3 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.21 M
52 Week Range
3.49 - 26.95
% held by Insiders
24.9 %
% held by Institutions
63.25 %
Enterprise Value
824.50 M
Total Shares
83.78 M
Short %
32.41 %
Float Shares
58.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Corvus Pharmaceuticals, Inc.
559Total events
5Upcoming
68Tier-1 (high impact)
2016 – 2028Coverage
Upcoming catalysts 5
Event history 554
Jun 8, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference presentation
Jun 3, 2026
May 16, 2026
◆Late-BreakerSoquelitinibPresentation
Late-breaking oral presentation: Soquelitinib produces prolonged drug-free remissions in atopic dermatitis
atopic dermatitissource ↗
May 16, 2026
◆Oral PresentationSoquelitinibPresentation
Soquelitinib, an ITK inhibitor, Produces Prolonged Drug-Free Remissions in Atopic Dermatitis
atopic dermatitissource ↗
May 14, 2026
◆Oral PresentationSoquelitinibPresentation
Oral presentation: Immunologic and clinical activity of soquelitinib in atopic dermatitis
atopic dermatitissource ↗
May 14, 2026
◆R&D DaySoquelitinibPresentation
Investor and analyst meeting to highlight soquelitinib data
atopic dermatitissource ↗
May 14, 2026
◆Enrollment UpdateSoquelitinibTrial
Enrolling patients in Phase 2 SIERRA1 trial
atopic dermatitissource ↗
May 7, 2026
May 7, 2026
◆Oral PresentationSoquelitinibPresentation
Two oral presentations at SID annual meeting reviewing Phase 1 atopic dermatitis data
atopic dermatitissource ↗
Apr 23, 2026
Mar 12, 2026
Drug Pipeline Intelligence
C48
Pipeline Score $724M
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored2.3x
rNPV / MCap Top 71%
Micro Cap (rank 265 of 912)
Percentile RankCorvus Pharmaceuticals, Inc. carries a moderate pipeline score (48/100), with $1.8B risk-adjusted pipeline value, led by Soquelitinib in Atopic Dermatitis (Phase 2), across $96B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Soquelitinib Small molecule | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 3 | NCT06561048 | 56% | $1.4B | RECRUITING | 150 | STALLED | C (52) | Dec 1, 2028 | LOW_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
soquelitinib Fast TrackOrphan | atopic dermatitis | Phase 1 | 2026-05-08 | Phase 1 cohort 4 positive data | Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results Read More | |
soquelitinib Fast TrackOrphan | atopic dermatitis | Phase 1 | 2026-05-08 | Phase 1 cohort 4 positive data | Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results Read More | |
soquelitinib Fast TrackOrphan | atopic dermatitis | Phase 1 | 2026-05-08 | Phase 1 cohort 4 positive data | Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRVS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRVSCorvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
Corvus Pharmaceuticals has invested $5 million in a $13.5 million financing round for Angel Pharmaceuticals, aimed at advancing the development of soquelitinib in China. This funding will support ongoing clinical trials for atopic dermatitis and asthma. Results from the Phase 1b trial are expected by late 2026, with a Phase 2 asthma trial set to begin in early 2027.
Read more →CRVS▲ +6%on this news
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Corvus Pharmaceuticals, Inc. is set to present at the 2026 Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Members of the leadership team will conduct one-on-one meetings with investors and provide a corporate overview during these events. The presentations are scheduled for June 3 and June 8, 2026, respectively, and will include a live webcast available for 90 days post-event. The company is focused on developing ITK inhibitors as a new approach to treating various immune diseases and cancers.
Read more →CRVS▼ -13.8%on this news· ran to -27% by day 3
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals presented promising final data from a Phase 1 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis at the SID Annual Meeting. The study showed that soquelitinib enhances immune regulation by increasing Treg cells and decreasing inflammatory responses, potentially leading to sustained remission after treatment cessation. Notably, the treatment demonstrated favorable safety and efficacy outcomes, with no significant adverse events reported. Further investigations are expected to explore its therapeutic potential for challenging cases of atopic dermatitis.
Read more →CRVS▲ +6.6%on this news
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Corvus Pharmaceuticals has reported positive developments regarding its lead candidate, soquelitinib, for treating atopic dermatitis, with Phase 1 data indicating potential for drug-free remissions. The company plans to present additional data at the Society for Investigative Dermatology meeting. Financially, Corvus holds significant cash reserves, though it reported a net loss in the first quarter of 2026 compared to the previous year.
Read more →CRVS▼ -10.3%on this news
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
Corvus Pharmaceuticals has appointed Dr. Andrew C. Chan to its Board of Directors. Dr. Chan brings over 25 years of experience from Genentech, where he led research in various therapeutic areas. His expertise in immunology is expected to significantly contribute to Corvus's development of ITK inhibitors, particularly in treating immune and inflammatory diseases.
Read more →CRVS▲ +10.3%on this newsshared move
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals announced it will host an investor and analyst meeting on May 14, 2026, to discuss data on soquelitinib presented at the Society for Investigative Dermatology Annual Meeting. The meeting will feature two oral presentations focusing on a Phase 1 clinical trial for atopic dermatitis, showcasing new immunologic and biomarker data. Key speakers include renowned experts from Stanford University, and a replay of the meeting will be available on the company's website. The company will also report its first quarter 2026 financial results shortly before the meeting.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Corvus Pharmaceuticals reported a positive business update, highlighting successful results from cohort 4 of the soquelitinib Phase 1 trial for atopic dermatitis, and the initiation of a Phase 2 trial. The company raised $189 million through a public offering, extending its cash runway into 2028. However, it also reported a net loss of $12.3 million for Q4 2025, driven by increased R&D expenses.
Read more →CRVS▼ -10%on this news
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced a conference call scheduled for March 12, 2026, to provide a business update and share fourth quarter financial results for 2025. The event will be accessible via toll-free numbers and through a live webcast available on the company's website. Corvus is focused on ITK inhibition, with its lead candidate soquelitinib undergoing significant clinical assessments for various immune diseases and cancer indications.
Read more →CRVSCorvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Corvus Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company's leadership will conduct one-on-one meetings with investors and provide a corporate overview. A webcast of the presentation will be available for live viewing and for 90 days afterward. Corvus is focused on developing ITK inhibition therapies for immune diseases and cancer.
Read more →CRVS▼ -8.3%on this news
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
Corvus Pharmaceuticals announced the successful closing of an upsized public offering, raising approximately $201 million. The offering included the full exercise of the underwriters' option to purchase additional shares. Proceeds will be used for working capital, including funding for ongoing clinical trials in T cell lymphoma and atopic dermatitis.
Read more →CRVS▲ +15.2%on this newsshared move
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Corvus Pharmaceuticals announced the pricing of an upsized public offering, selling 7,900,677 shares at $22.15 each, aiming to raise around $175 million. The proceeds will be used for working capital, including funding clinical trials for various conditions. The offering is set to close on January 23, 2026, pending customary conditions.
Read more →CRVSCorvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Corvus Pharmaceuticals has announced a proposed public offering of $150 million in common stock and pre-funded warrants. The company plans to use the proceeds for working capital and various clinical trials, including Phase 3 and Phase 2 studies. The offering is contingent on market conditions, and there are no assurances regarding its completion or terms.
Read more →CRVS▲ +166%on this news· ran to +212% by day 3shared move
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals announced positive results from cohort 4 of its Phase 1 clinical trial for soquelitinib in treating moderate to severe atopic dermatitis. The data showed that 75% of patients achieved significant improvement in their condition, with no new safety concerns reported. The company plans to initiate a Phase 2 trial in early 2026 to further evaluate the drug's efficacy.
Read more →CRVS▲ +166%on this news· ran to +212% by day 3shared move
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals will announce results from cohort 4 of its Phase 1 clinical trial for soquelitinib, targeting moderate to severe atopic dermatitis. The announcement will take place during a conference call on January 20, 2026. Soquelitinib is also involved in a Phase 3 trial for relapsed/refractory PTCL. The company emphasizes the potential risks associated with forward-looking statements regarding trial outcomes.
Read more →CRVS▼ -7.2%on this news
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
Corvus Pharmaceuticals has confirmed it will announce results from cohort 4 of its Phase 1 clinical trial for soquelitinib in January 2026. The trial focuses on patients with moderate to severe atopic dermatitis. In light of the upcoming data, the company has canceled its participation in the J.P. Morgan 2026 Healthcare Conference.
Read more →CRVSCorvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals has presented final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma at the 67th American Society of Hematology Annual Meeting. Results show a median progression free survival of 6.2 months and a median overall survival of 28.1 months, which is favorable compared to other treatments. The data supports further development of soquelitinib in oncology and inflammatory diseases, indicating possible future applications beyond T cell lymphoma. A registration Phase 3 trial for soquelitinib in relapsed/refractory PTCL is currently ongoing, aiming to enroll 150 patients.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Corvus Pharmaceuticals has completed enrollment in a Phase 1 trial extension for soquelitinib and plans to initiate a Phase 2 trial for atopic dermatitis in early Q1 2026. The Phase 3 trial for relapsed/refractory peripheral T cell lymphoma is ongoing, with final Phase 1/1b results accepted for presentation at an upcoming meeting. Financially, the company reported a reduced net loss for Q3 2025 compared to the previous year.
Read more →CRVSCorvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Corvus Pharmaceuticals announced that final data from its Phase 1/1b trial of soquelitinib for T cell lymphoma will be presented at the 67th ASH Annual Meeting in December 2025. The oral presentation is scheduled for December 8, 2025, highlighting the efficacy of soquelitinib, an ITK inhibitor. This trial is part of Corvus's broader development strategy for immunotherapy in cancer treatment.
Read more →CRVSCorvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Corvus Pharmaceuticals will present at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025. The company's leadership will engage in one-on-one meetings with investors and participate in a fireside chat. A webcast of the event will be available for 90 days post-conference.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Corvus Pharmaceuticals has announced a conference call scheduled for November 4, 2025, to provide a business update and report its financial results for the third quarter of 2025. The event will be accessible to the public through a toll-free phone line and a webcast. Corvus is noted for its clinical-stage development of ITK inhibitors as an innovative strategy in immunotherapy targeting cancer and immune diseases. The company aims to enhance investor engagement by providing timely updates on its progress.
Read more →CRVS▼ -7.1%on this news
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Corvus Pharmaceuticals presented interim data from its Phase 1b/2 trial of ciforadenant for metastatic renal cell cancer at the ESMO Congress 2025. The trial evaluates ciforadenant in combination with ipilimumab and nivolumab as a first-line therapy. Early results indicate that the triplet therapy is feasible and well tolerated, showing promising activity in patients with unfavorable disease.
Read more →CRVSCorvus Pharmaceuticals Appoints David Moore to Board of Directors
Corvus Pharmaceuticals has appointed David Moore to its Board of Directors. Moore, who has a rich background in the pharmaceutical industry, is expected to contribute significantly to the company's strategic initiatives, particularly in advancing its ITK inhibitor platform. His previous experience includes leadership roles at Novo Nordisk and other biopharma companies.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
Corvus Pharmaceuticals has provided a business update and reported its financial results for the second quarter of 2025. The Phase 1 trial of soquelitinib for atopic dermatitis shows promising results with significant improvements in symptom scores. The company is on track to initiate a Phase 2 trial and has started enrolling patients in a Phase 3 trial for relapsed/refractory peripheral T cell lymphoma. Financially, Corvus raised $35.7 million through stock warrants, despite reporting an increased net loss and rising R&D expenses.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
Corvus Pharmaceuticals has scheduled a conference call and webcast for August 7, 2025, to discuss its business operations and report its second quarter financial results. The event will be accessible via toll-free and international dialing options, and a live webcast is also available. This update is particularly significant as it reflects ongoing developments in the company's clinical-stage biopharmaceutical endeavors, including their lead candidate, soquelitinib.
Read more →CRVS▼ -5.1%on this news
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
Corvus Pharmaceuticals announced that its partner, Angel Pharmaceuticals, received IND approval to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis in China. The trial aims to explore a longer treatment period and additional dosing options. Patient enrollment is expected to begin in Q3 2025, with data anticipated in 2026. Corvus continues its development of soquelitinib in the U.S. with plans for a Phase 2 trial.
Read more →CRVS▲ +5.9%on this news
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
Corvus Pharmaceuticals presented preclinical data on soquelitinib's potential to treat systemic sclerosis at the EULAR 2025 Congress. The data suggests that ITK inhibition may prevent lung damage and inflammation associated with the disease. The presentation was recognized as a top 10 abstract by EMEUNET, highlighting its significance in rheumatology research.
Read more →CRVS▼ -9%on this news
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals has released positive interim results from Cohort 3 of their Phase 1 clinical trial for soquelitinib, a treatment for moderate to severe atopic dermatitis. The cohort showed significant improvement in the Eczema Area and Severity Index (EASI) at day 28, with early indications of response starting at day 8. A separate extension cohort study has also been initiated to further explore the treatment's effectiveness over a longer duration. Overall, the data points to soquelitinib's potential as a safe and effective option for patients with atopic dermatitis.
Read more →CRVSCorvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Corvus Pharmaceuticals, Inc. announced its participation in the 2025 Jefferies Global Healthcare Conference, where its leadership team will hold one-on-one meetings and present a corporate overview. The presentation is scheduled for June 5, 2025, from 9:20 to 9:50 am ET. A live webcast of the presentation will also be made available for 90 days, providing further engagement opportunities for investors. The company focuses on ITK inhibition as a new approach to immunotherapy for various cancers and immune diseases.
Read more →CRVSCorvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals announced promising interim data from its Phase 1 clinical trial of soquelitinib in patients with moderate to severe atopic dermatitis. The results indicated a favorable safety and efficacy profile, particularly in cohort 3, which experienced earlier and deeper responses. The trial totalled 48 patients, with significant reductions in EASI scores for soquelitinib compared to placebo. The company plans to extend the treatment period for additional patients to potentially enhance efficacy further as they prepare for a Phase 2 trial.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Corvus Pharmaceuticals reported favorable interim results from its phase 1 trial of soquelitinib for atopic dermatitis, indicating improved efficacy in later cohorts. The company announced the ongoing enrollment in a phase 3 trial for soquelitinib in relapsed peripheral T cell lymphoma, which has received orphan drug designation from the FDA. Financially, Corvus generated $31.3 million through the early exercise of stock warrants, while also reporting a net income of $15.2 million for Q1 2025. The update reflects the company's ambitious plans to continue advancing its pipeline and clinical trials.
Read more →CRVS▲ +5.7%on this news
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
Corvus Pharmaceuticals will present new interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis at the Society for Investigative Dermatology 2025 Annual Meeting. The presentations will include both an oral and a poster session, with details on timing provided. Additionally, the company plans to discuss this new data during its first quarter 2025 business update conference call on May 8, 2025. The trial aims to evaluate the efficacy of soquelitinib, an ITK inhibitor, for patients with moderate to severe atopic dermatitis.
Read more →CRVSCorvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
Corvus Pharmaceuticals has appointed Richard A. van den Broek to its board of directors. Mr. van den Broek brings over 30 years of experience in the life sciences industry and has previously served on the board of Pharmacyclics. He expressed his excitement about joining Corvus as it develops ITK inhibition, which he believes can significantly help patients with immune diseases and cancers. His background and knowledge are expected to contribute positively to the company's ongoing clinical advances.
Read more →CRVS▼ -7.5%on this news· ran to -21% by day 1
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Corvus Pharmaceuticals released a business update highlighting advancements in their product soquelitinib, designed for treating various conditions including atopic dermatitis and peripheral T cell lymphoma (PTCL). Initial results from a Phase 1 trial show promising safety and efficacy data for soquelitinib in atopic dermatitis, with the Phase 3 trial for PTCL currently enrolling patients. The company also initiated a Phase 2 trial for autoimmune lymphoproliferative syndrome in partnership with NIAID. Financially, Corvus reported a significant increase in cash reserves compared to the previous year, supporting further development of their clinical programs.
Read more →CRVSCorvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
Corvus Pharmaceuticals has presented additional data from its Phase 1/1b clinical trial of soquelitinib for treating T cell lymphoma at the Annual T-Cell Lymphoma Forum. The trial showed promising results, including a high complete response rate and favorable median progression-free survival compared to existing treatments. Patient samples indicated that soquelitinib reduces T cell exhaustion, potentially enhancing anti-tumor immunity. A registrational Phase 3 clinical trial is now underway, evaluating soquelitinib against standard therapies.
Read more →CRVS▼ -5.8%on this newsshared move
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Corvus Pharmaceuticals announced its participation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. Members of the leadership team will hold one-on-one investor meetings and present during a fireside chat on March 27, 2025. A webcast of the chat will be available live and for 90 days post-event. This engagement reflects the company's ongoing commitment to advancing its immunotherapy development efforts.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Corvus Pharmaceuticals has announced a conference call and webcast scheduled for March 25, 2025, to provide a business update and report on its financial results for the fourth quarter and full year of 2024. The call can be accessed via telephone or through a live webcast on the company's investor relations page. This follows the company's ongoing development of innovative treatments, such as ITK inhibition for various cancer and immune disease indications.
Read more →CRVS▲ +5.9%on this newsshared move
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
Corvus Pharmaceuticals has announced the initiation of a Phase 2 clinical trial for soquelitinib, aimed at treating autoimmune lymphoproliferative syndrome (ALPS) in partnership with the NIH's NIAID. This trial will involve up to 30 patients aged 16 or older with confirmed ALPS-FAS, focusing on measuring efficacy through reductions in splenomegaly and lymph node volumes. The lead investigator, Dr. V. Koneti Rao, has previously presented encouraging preclinical data highlighting the drug's potential in addressing immune dysregulation associated with ALPS. Soquelitinib is also being developed for other indications, including peripheral T cell lymphoma and atopic dermatitis.
Read more →CRVS▲ +5.3%on this news
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Corvus Pharmaceuticals announced that its leadership team will present a corporate overview and engage in one-on-one meetings with investors at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The event will be held virtually on February 11, 2025, and will include a live webcast of the presentation accessible for 90 days afterward. This participation highlights Corvus's commitment to stakeholder engagement and its progress in developing novel immunotherapy solutions.
Read more →CRVSCorvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Data continue to demonstrate a favorable safety and efficacy profile, including impro
Corvus Pharmaceuticals has announced promising interim data from Cohort 2 of their Phase 1 clinical trial of soquelitinib for treating atopic dermatitis. The results indicate a favorable safety and efficacy profile, with significant improvements observed in key efficacy endpoints compared to placebo. No major safety concerns were reported, enabling continued excitement about the drug's potential. Full results from the trial are expected in the second quarter of 2025, alongside ongoing trials for other indications.
Read more →CRVSCorvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Corvus Pharmaceuticals, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, taking place from January 13-16, 2025. The event will feature a presentation by CEO Richard A. Miller, M.D., on January 15 at 2:15 PM ET. The company will also conduct one-on-one meetings with investors during the conference. An audio webcast of the presentation will be available live and for 30 days afterward, accessible via the company's investor relations webpage.
Read more →CRVS▼ -36.4%on this news
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile D
Corvus Pharmaceuticals has released interim data from its Phase 1 clinical trial of soquelitinib for treating moderate to severe atopic dermatitis. The data shows a favorable safety and efficacy profile, particularly at the lowest dose being tested, highlighting the potential for soquelitinib as a new treatment option. Early results from cohort 1 indicate significant improvements in both efficacy measures and cytokine levels. The trial is progressing with further enrollment and analysis planned for additional cohorts.
Read more →CRVS▲ +7.1%on this news· ran to -32% by day 1shared move
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Corvus Pharmaceuticals is set to announce interim data from its placebo-controlled Phase 1 clinical trial of soquelitinib for patients with moderate to severe atopic dermatitis on December 18, 2024. This investigational drug aims to selectively inhibit ITK, influencing T cell immune responses. The data will be discussed in a press release and during a conference call, which will also provide insights on soquelitinib's potential applications in other autoimmune and cancer-related treatments. Previous studies have indicated its effectiveness in treating refractory T cell lymphomas, supporting its potential broader therapeutic impact.
Read more →CRVSCorvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Corvus Pharmaceuticals announced the publication of preclinical data for soquelitinib, their lead ITK inhibitor, showcasing its potential to modulate tumor immunity. The research, published in npj Drug Discovery, highlights soquelitinib's mechanism that suppresses Th2 and Th17 cytokine production while enhancing Th1 cytokines. The company is advancing clinical development for conditions such as relapsed peripheral T cell lymphoma (PTCL) and atopic dermatitis, with ongoing trials indicating the drug's viability in oncology and immune diseases.
Read more →CRVSCorvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals has announced new preclinical data demonstrating the potential of soquelitinib, its lead ITK inhibitor, in preventing lung damage from systemic sclerosis. The findings show significant improvements in lung infiltration and pulmonary hypertension in treated mouse models compared to controls. The data will be presented at the ACR Convergence 2024, underscoring the therapeutic potential of soquelitinib for immune-mediated fibrotic diseases. The company continues to focus on its Phase 3 trial for peripheral T cell lymphoma and a Phase 1 trial in atopic dermatitis.
Read more →CRVS▼ -9.1%on this newsshared move
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Corvus Pharmaceuticals has reported third quarter 2024 financial results, showing significant enrollment progress in clinical trials for their lead candidate, Soquelitinib. Notably, a Phase 1 trial for atopic dermatitis is currently enrolling a second cohort, with interim data expected in December 2024. The company also continues to advance a Phase 3 registration trial for Soquelitinib in patients with relapsed peripheral T cell lymphoma. Despite a reported net loss of $40.2 million, Corvus maintains a positive outlook on their product pipeline and funding strategy.
Read more →CRVSCorvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Corvus Pharmaceuticals announced new promising data regarding ciforadenant, an adenosine A2A receptor antagonist, at the SITC Annual Meeting. The findings indicate ciforadenant's potential to enhance anti-PD1 immunotherapy efficacy in patients with metastatic castration-resistant prostate cancer. The study highlights the significance of SPP1+ myeloid cells in immunotherapy resistance and supports ongoing clinical trials combining ciforadenant with other agents. The results suggest a shift in treatment paradigms for prostate cancer patients resistant to current therapies.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
Corvus Pharmaceuticals announced it will host a conference call and webcast on November 12, 2024, to provide a business update and report its third quarter financial results for 2024. This event reflects the company's commitment to transparency and keeping stakeholders informed about its financial health and business direction. Corvus is recognized for its innovative approach to cancer and immune disease treatment through ITK inhibition. The webcast will be available for replay for 90 days on the Corvus website.
Read more →CRVS▲ +13.9%on this news· ran to +25% by day 3
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Corvus Pharmaceuticals has initiated a Phase 3 clinical trial for its drug soquelitinib to treat relapsed/refractory peripheral T-cell lymphoma (PTCL). The trial will enroll approximately 150 patients to compare the efficacy and safety of soquelitinib against standard chemotherapy. Soquelitinib, an investigational ITK inhibitor, has received FDA Orphan Drug and Fast Track designations, underscoring its potential in addressing a treatment gap in this patient population. The trial is set to take place across multiple sites in the United States, Canada, Australia, and South Korea.
Read more →CRVS▼ -9.8%on this news
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) has announced its participation at the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9-11, 2024, in New York. CEO Richard A. Miller and CBO Jeffrey Arcara will conduct one-on-one meetings with investors and present a corporate overview. The presentation is scheduled for September 10 at 12:00 PM ET, and a live webcast will be available along with a recording for 90 days after the conference.
Read more →CRVS▲ +6.4%on this news· ran to +41% by day 3
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
Corvus Pharmaceuticals has provided a business update alongside its financial results for Q2 2024. The company announced positive early results from its Phase 1 trial of soquelitinib in atopic dermatitis, with indications of clinical activity and mechanism engagement. Corvus aims to initiate a Phase 3 registrational trial for peripheral T cell lymphoma (PTCL) in the third quarter of 2024, with hopes bolstered by recent Fast Track designation from the FDA. Despite reporting a net loss for the quarter, the company has improved its cash position significantly from earlier in the year.
Read more →CRVS▲ +16.3%on this newsshared move
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Corvus Pharmaceuticals has received FDA Fast Track Designation for soquelitinib, aimed at treating adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This designation highlights the considerable unmet need for effective treatments in this patient population, which currently lacks FDA-approved options. The company is set to initiate patient enrollment in a registrational Phase 3 clinical trial in Q3 2024. Additionally, soquelitinib has shown promise in preliminary trials, stirring significant interest from clinical investigators.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
Corvus Pharmaceuticals, Inc. has announced a scheduled conference call and webcast for August 6, 2024, at 4:30 PM ET to present a business update and financial results for the second quarter of 2024. The event will be accessible via telephone and live webcast, with a 90-day replay available on the company's website. Corvus is focused on developing immunotherapy treatments for cancer and immune diseases, including its lead candidate, soquelitinib.
Read more →CRVSCorvus Pharmaceuticals to Present at the Jefferies Global Health Conference
Corvus Pharmaceuticals, Inc. announced that it will present at the Jefferies Global Health Conference in New York from June 5-7, 2024. CEO Richard A. Miller and CBO Jeffrey Arcara will meet with investors and provide a corporate overview. The presentation is scheduled for June 5 at 3:00 pm ET, and a webcast will be available for 90 days afterward. Corvus specializes in ITK inhibition for cancer and immune diseases, with its lead candidate soquelitinib currently in clinical development.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Corvus Pharmaceuticals has reported promising advancements in its clinical trials and financial standing. The company is enrolling patients for the Phase 1 trial of soquelitinib in atopic dermatitis while also preparing for a Phase 3 trial in relapsed peripheral T-cell lymphoma. Interim results for ciforadenant show data exceeding predefined response thresholds in renal cell cancer treatment. Additionally, the company secured $30.6 million in financing to enhance its clinical and commercial strategies.
Read more →CRVS▲ +7.5%on this news· ran to +19% by day 1shared move
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
Corvus Pharmaceuticals has announced a conference call scheduled for May 6, 2024, to provide a business update and report its financial results for the first quarter of 2024. This event will be accessible via telephone and web, promoting transparency and investor engagement. The company is focused on developing innovative immunotherapy treatments for cancer and immune diseases, with its lead candidate being soquelitinib. This update signifies the company's ongoing commitment to advancing its business and communicating with stakeholders.
Read more →CRVS▲ +7.5%on this news· ran to +19% by day 1shared move
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
Corvus Pharmaceuticals has announced a registered direct offering aimed at raising approximately $30.6 million through the sale of common stock and pre-funded warrants. The offering will involve notable healthcare investors and is expected to close around May 6, 2024. No underwriting fees or placement agent expenses will be incurred, making the deal financially favorable for the company. The proceeds from the offering will contribute to the company’s ongoing clinical programs and development initiatives.
Read more →CRVSCorvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals has initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial to evaluate its investigational drug soquelitinib in patients with moderate to severe atopic dermatitis. The trial aims to enroll 64 patients across 12 sites in the United States, with initial data expected by the end of 2024. Soquelitinib is designed to inhibit multiple cytokines involved in inflammation, potentially offering a new oral treatment option compared to existing injectable therapies. The company has previously noted promising preclinical results, further supporting the drug's clinical evaluation.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Corvus Pharmaceuticals has announced a business update and reported its financial results for the fourth quarter and full year of 2023. The company is advancing its lead compound, soquelitinib, into a Phase 3 clinical trial for relapsed peripheral T cell lymphoma (PTCL) and is planning a randomized trial for atopic dermatitis. Notably, soquelitinib has received Orphan Drug Designation from the FDA, highlighting its potential in addressing the unmet need in treatment options for PTCL. However, the company faces challenges, including a significant decline in cash reserves compared to the previous year.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
Corvus Pharmaceuticals has announced a conference call scheduled for March 19, 2024, where it will provide a business update and report its financial results for the fourth quarter and full year of 2023. The event will include discussions on the progress of its clinical-stage candidates, including the lead product candidate soquelitinib, which targets immune diseases and cancer. The financial results may give investors insights into the company's advancement and future prospects.
Read more →CRVSCorvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
Corvus Pharmaceuticals announced the presentation of preclinical data for its lead ITK inhibitor, soquelitinib, at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases. The data outlines the development of next-generation ITK inhibitors that could improve treatment for various diseases, including asthma and psoriasis, by modulating T-cell function. The research indicates soquelitinib's potential effectiveness across several T cell-mediated inflammatory diseases, with plans for a Phase 3 clinical trial in relapsed peripheral T cell lymphoma.
Read more →CRVSCorvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
Corvus Pharmaceuticals announced that the FDA granted Orphan Drug Designation to its investigational drug, soquelitinib, for treating T cell lymphoma. This designation is significant as it indicates recognition of the therapeutic potential of soquelitinib in a disease area where there are limited existing treatments. The company plans to initiate a Phase 3 clinical trial for relapsed peripheral T cell lymphoma in Q2 2024. This trial follows promising early results indicating the drug's effectiveness in treating difficult-to-manage cases of T cell malignancies.
Read more →CRVSCorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
Corvus Pharmaceuticals announced the appointment of Jeffrey Arcara as Chief Business Officer. With over 30 years in the biopharmaceutical sector, Arcara will lead corporate strategy and business development for Corvus. His expertise in commercial roles is expected to enhance the firm's programs in ITK inhibition for cancer and immune diseases. The company plans to conduct a Phase 3 trial for its lead candidate, soquelitinib, aiming to address unmet treatment needs.
Read more →CRVSCorvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
Corvus Pharmaceuticals has announced the passing of Edith P. Mitchell, M.D., a respected member of its Board of Directors. Dr. Mitchell, who served on the board since September 2020, had a notable career in healthcare and was recognized for her contributions to cancer care and health equity. The company expressed deep condolences to her family and colleagues, noting her impactful legacy in oncology and healthcare. Dr. Mitchell was also a pioneer as the first female Brigadier General in the U.S. Air Force.
Read more →CRVS▼ -16.1%on this news
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals has shared new interim data from its Phase 1/1b clinical trial of soquelitinib for patients with relapsed peripheral T cell lymphoma (PTCL). The results indicate durable anti-tumor activity, with outcomes such as progression-free survival and overall survival rates that surpass current standard treatments. The company confirms patient eligibility criteria and aims to advance into a Phase 3 registrational clinical trial based on the favorable results observed in this trial. Notably, the data supports soquelitinib's potential as a novel treatment approach in this challenging therapeutic area.
Read more →CRVS▲ +6.8%on this news
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Corvus Pharmaceuticals has finalized the protocol for its Phase 3 registrational trial of soquelitinib (CPI-818) in patients with peripheral T cell lymphoma, with enrollment expected to begin by Q2 2024. Recent data from the Phase 1 trial demonstrate tumor regression, bolstering the drug's prospects. Additionally, exciting new preclinical findings underscore the potential for ITK inhibition in treating other diseases, including solid tumors and autoimmune conditions. Financially, Corvus reported cash reserves of approximately $32.2 million and a decreased net loss compared to last year.
Read more →CRVSCorvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
Corvus Pharmaceuticals announced it will present new interim data from its Phase 1/1b trial of soquelitinib for relapsed peripheral T cell lymphoma at the upcoming 65th American Society of Hematology Annual Meeting. The presentation will include insights on the immune regulatory mechanisms of soquelitinib, which is designed to selectively inhibit ITK. Following positive interim results, Corvus plans to initiate a Phase 3 clinical trial for soquelitinib in patients with this challenging condition.
Read more →CRVSCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
Corvus Pharmaceuticals has announced the publication of preclinical data on soquelitinib, highlighting its potential as an ITK inhibitor for treating T cell-mediated inflammatory and immune diseases. The research shows significant activity in various disease models, including asthma and systemic sclerosis. This novel mechanism of action could outperform current therapies by targeting upstream cytokine production. Corvus aims to advance soquelitinib through clinical trials for several indications, bolstering its pipeline of next-generation ITK inhibitors.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
Corvus Pharmaceuticals has announced a conference call and webcast scheduled for November 7, 2023, to provide a business update and report its financial results for the third quarter of 2023. The company, which focuses on ITK inhibition for cancer treatment, is preparing to initiate a Phase 3 trial for its lead candidate, soquelitinib. Investors can access the call via telephone or through the company's website, with a replay available for 90 days following the event.
Read more →CRVSCorvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
Corvus Pharmaceuticals has confirmed that it will initiate a Phase 3 registrational clinical trial for soquelitinib in relapsed peripheral T cell lymphoma after a successful meeting with the FDA. The trial is expected to enroll 150 patients and aims to assess the drug's effectiveness compared to standard chemotherapy. The primary endpoint will be progression-free survival, with additional endpoints evaluating objective response and overall survival. The company aims to begin the trial in the first quarter of 2024, reinforcing its commitment to advancing ITK inhibition therapy for lymphoma and potentially other indications.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
Corvus Pharmaceuticals has provided a business update along with its second quarter 2023 financial results, highlighting the potential of its lead candidate, soquelitinib, as a novel immunotherapy for various cancers. The company is in the process of enrolling patients for a Phase 1/1b trial targeting relapsed T cell lymphomas and anticipates engaging with the FDA for a Phase 3 trial discussion. Interim results from this trial indicate promising clinical outcomes, while preclinical studies reveal soquelitinib's capabilities in enhancing anti-tumor responses. However, Corvus reported a net loss during the quarter and expects its cash reserves to sustain operations only through the latter part of 2024.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, announced it will host a conference call and webcast on August 8, 2023, to provide a business update along with its second quarter 2023 financial results. The call will be accessible via a toll-free number and can also be viewed through a live webcast on the company's website. Corvus is known for its work in developing immunotherapies for various cancers, particularly with its lead product candidate, soquelitinib, currently in mid-stage trials for T cell lymphoma.
Read more →CRVSCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
Corvus Pharmaceuticals announced the publication of preclinical data showcasing soquelitinib's potential as a novel immunotherapy targeting ITK inhibition. The research highlights the drug's ability to enhance anti-tumor immune responses in various cancers. The publication, resulting from collaborative efforts among multiple universities, reveals that soquelitinib may lead to effective T cell activation and reduced exhaustion, addressing significant barriers in cancer immunotherapy. Corvus plans to discuss a potential Phase 3 registration trial for soquelitinib with the FDA in Q3 2023.
Read more →CRVS▼ -5.1%on this news
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
Corvus Pharmaceuticals has presented new preclinical data for ciforadenant at the JCA-AACR Precision Cancer Medicine International Conference. The data confirms ciforadenant's mechanism of action and its synergy with immune checkpoint inhibitors when combined with anti-CTLA-4 and anti-PD-1 therapies. The ongoing Phase 1b/2 clinical trial aims to evaluate ciforadenant as a first-line therapy for metastatic renal cell cancer, with initial results anticipated before the year's end. The findings support the rationale for this combination therapy in enhancing the immune response against cancer.
Read more →CRVS▼ -25.7%on this news
Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma
Corvus Pharmaceuticals presented interim data on CPI-818 at the International Conference on Malignant Lymphoma, highlighting its potential as a novel immunotherapy approach for various solid and hematological cancers. The Phase 1/1b trial results showed favorable outcomes with a majority of patients experiencing tumor regression after treatment. The company plans to engage with the FDA in the third quarter of 2023 to discuss a Phase 3 clinical trial design focusing on T cell lymphoma. The findings demonstrate CPI-818's ability to enhance immune response and reduce T cell exhaustion, supporting its use as a possible monotherapy or in combination therapies.
Read more →CRVSCorvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
Corvus Pharmaceuticals announced that CEO Richard A. Miller will present a corporate overview and hold one-on-one meetings with investors at the Jefferies Healthcare Conference in New York from June 7-9, 2023. The presentation is scheduled for June 7 at 9:30 am ET. A live webcast will be available, allowing broader access to the company's insights. Corvus focuses on innovative immunotherapy approaches, particularly involving its lead candidate CPI-818, aimed at treating T cell lymphoma.
Read more →CRVS▲ +36.7%on this news
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
Corvus Pharmaceuticals announced it will present new data on its ITK inhibitor CPI-818 at the upcoming International Conference on Malignant Lymphoma in June 2023. The presentation will include insights from a Phase 1/1b clinical trial targeting T cell lymphoma, where CPI-818 has demonstrated promising results. The company remains on track to potentially initiate a Phase 3 trial later this year and plans discussions with the FDA regarding future clinical development steps. CPI-818 aims to enhance immune responses against tumors and is being evaluated for various hematologic and solid cancers.
Read more →CRVS▲ +8.3%on this news· ran to +69% by day 3
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
Corvus Pharmaceuticals has provided a business update and reported its financial results for Q1 2023. The company highlighted promising interim results for CPI-818, an investigational ITK inhibitor, particularly in patients with T cell lymphomas. With encouraging clinical data supporting the treatment, Corvus plans to advance towards a possible Phase 3 trial later this year. However, the company is facing challenges with a decrease in cash reserves and a steady net loss.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Corvus Pharmaceuticals, Inc. announced it will host a conference call on May 8, 2023, to provide a business update and report its financial results for the first quarter of 2023. The call will be accessible via phone and webcast, and a replay will be available for 90 days on the company's website. Corvus has several investigational drugs in its pipeline, including CPI-818, which is currently undergoing Phase 1/1b clinical trials.
Read more →CRVS▲ +6.7%on this newsshared move
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
Corvus Pharmaceuticals has presented new preclinical data for its ITK inhibitor CPI-818 at the AACR Annual Meeting, revealing its potential for treating multiple types of solid and hematological cancers. The data shows significant tumor growth inhibition across different cancer models and highlights the drug's mechanism of action, which enhances T cell differentiation and immune efficacy. The company continues to enroll patients in a Phase 1/1b clinical trial, aiming for a future discussion with the FDA regarding a potential Phase 3 randomized trial.
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Corvus Pharmaceuticals reported its fourth quarter and full year 2022 financial results, highlighting advancements in the CPI-818 program for lymphoma therapies. The company has identified a predictive biomarker that may enhance patient selection for treatment, resulting in accelerated enrollment in clinical trials. While there are positive updates, Corvus is delaying the Phase 1 trial for atopic dermatitis to focus on T cell lymphoma due to cash conservation efforts. The company maintains a solid pipeline with potential developments from partner-led programs.
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
Corvus Pharmaceuticals announced a conference call scheduled for March 28, 2023, to provide a business update and disclose fourth quarter and full year 2022 financial results. The event will be accessible via phone and webcast, with a replay available on Corvus' website for 90 days. This update is part of the company's efforts to inform investors about its progress, particularly regarding its investigational product candidates.
Read more →CRVSCorvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Corvus Pharmaceuticals announced that it will present new data on CPI-818, its ITK inhibitor, at the upcoming AACR Annual Meeting. The preclinical data indicates strong anti-tumor activity, particularly when used in combination with other therapies, achieving complete tumor elimination in a murine colon cancer model. This compelling efficacy lays the groundwork for the potential initiation of human clinical trials for CPI-818 in solid tumors. The company aims to explore the extensive potential of CPI-818 across oncology and immune diseases.
Read more →CRVSCorvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
Corvus Pharmaceuticals has announced promising new data supporting the potential of CPI-818, an ITK inhibitor, to manage HIV by reducing the need for lifelong antiretroviral therapy. Presented at the 30th Annual Conference on Retroviruses and Opportunistic Infections, the findings suggest that CPI-818 can inhibit HIV latency reversal. The research indicates that CPI-818 could significantly impact the long-term management of HIV, offering a 'block-and-lock' strategy for treatment. Ongoing studies aim to further explore CPI-818's applications in treating various conditions involving T cell function.
Read more →CRVSCorvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinica
Read more →CRVSCorvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
BURLINGAME, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an investor conference call to provide an update on CPI-818 data that will be p
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
Data From CPI-818 T Cell Lymphoma Study Accepted for Presentation at the 64th ASH Annual Meeting and Exposition; Advancing CPI-818 Development for Autoimmune and Allergic Diseases Initiation of a Phase 1b/2 Clinical Trial of Ciforadenant in First Line Renal Cell Cancer (RCC) in
Read more →CRVSCorvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
BURLINGAME, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, at the 64th American Soc
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
BURLINGAME, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on November 3, 2022 at 4:30 pm ET (1:30 pm PT) to provide a busi
Read more →CRVSCorvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
BURLINGAME, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line t
Read more →CRVSCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
BURLINGAME, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application to initiate a Phase 1/1b clinical trial of mupadolimab (formerly CPI-00
Read more →CRVSCorvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BURLINGAME, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, which is t
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases Plans to Begin Phase 2 Clinical Trial of Ciforadenant in Front Line Renal Cell Cancer (RCC) in Partnership with Kidney Cancer Consortium in Q3 2022 Pausing Start of Randomized Phase 2 Cli
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022
BURLINGAME, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on August 8, 2022 at 4:30 pm ET (1:30 pm PT) to provide a busine
Read more →CRVS▲ +7.4%on this news
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research
BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediat
Read more →CRVS▲ +8.9%on this news
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical and clinical data for its three programs – mupadolimab (anti-CD73), ciforadenant (adenosine 2A receptor antagonist) and CPI-818 (
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
BURLINGAME, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2022. “We are adv
Read more →CRVSCorvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York
BURLINGAME, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R&D Symposium to provide an update on the Company’s three clinical programs
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
BURLINGAME, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 3
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
BURLINGAME, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 10, 2022 at 4:30 pm ET (1:30 pm PT) to provide a busin
Read more →CRVSCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patie
Read more →CRVSCorvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy Corvus enrolling additional patients with these cancers in a Phase 1b/2 trial, with additional data anticipat
Read more →CRVSCorvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021. The Compa
Read more →CRVSCorvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
BURLINGAME, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer (SITC)
Read more →CRVS▲ +6.6%on this newsshared move
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2021. “Corvus is a leader in t
Read more →CRVSCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
BURLINGAME, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has been approved
Read more →CRVS▼ -12.2%on this news
Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease
Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab treated patients vs. placebo COVID-19 study immune response data found to be c
Read more →CRVSCorvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will participate in two upcoming investor conferences in September: The first conference
Read more →CRVSCorvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China
BURLINGAME, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that an IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), for the initiation
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
BURLINGAME, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2021. “We continue to advance mupa
Read more →CRVSCorvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations
Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies in an expansion cohort for patients with HPV+ (human papilloma virus) head and neck cancer Reduces projected 2021 net cash used in oper
Read more →CRVSCorvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 fr
Read more →CRVSCorvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program
BURLINGAME, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximately $10 million of its common shares pursuant to the Company’s ATM program esta
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
BURLINGAME, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2021. “In the first quarter we in
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
BURLINGAME, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020. “In 2020, we m
Read more →CRVSCorvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which inc
Read more →CRVSCorvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50 p
Read more →CRVSCorvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the o
Read more →CRVSCorvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure Randomized, double-blind, placebo-controlled study expected to enroll
Read more →CRVSCorvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition
Updated interim data from CPI-818’s phase 1/1b clinical trial provide evidence supporting its potential as a treatment for T cell lymphomas New pre-clinical data provide evidence of CPI-818 potential as a treatment for autoimmune lymphoproliferative syndrome (ALPS) BURLINGAME,
Read more →CRVSCorvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition
BURLINGAME, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company’s ITK inhibitor, will be presented at the 62nd American Society of Hematology (ASH)
Read more →CRVSCorvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting
Data shows CPI-006 provided enhanced and prolonged polyclonal humoral immunity to SARS-CoV-2 Plans to initiate pivotal, randomized, double blind trial in December with results expected mid-2021 BURLINGAME, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (
Read more →CRVSCorvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Data to be presented in a poster and an oral session “Hot Topic Symposium: COVID-19 and Cancer” at SITC Data shows CPI-006 provided enhanced and prolonged polyclonal humoral immunity to SARS-CoV-2 Plans to initiate pivotal, randomized, double blind trial in December with result
Read more →CRVSCorvus Pharmaceuticals COVID-19 Abstract Selected for “Hot Topic” Oral Session at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its abstract covering updated data from its Phase 1 study investigating the potential for CPI-006 to provide a novel
Read more →CRVSCorvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
BURLINGAME, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present updated data from its Phase 1 study investigating the potential for CPI-006 to provide a novel immun
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
BURLINGAME, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the third quarter ended September 30, 2020. “We have several import
Read more →CRVSCorvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China
Angel’s pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor program Strategic collaboration gives Corvus 49.7% equity stake and provides an opportunity to accelerate the development of the Corvus p
Read more →CRVSCorvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of Directors
BURLINGAME, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Edith P. Mitchell, M.D., has been appointed to the company’s Board of Directors. Dr. Mitchell has more than 45 year
Read more →CRVSCorvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19
Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org Patients treated in first two cohorts of Phase 1 study had low pre-treatment titers of antibodies and produced robust anti
Read more →CRVSCorvus Announces Participation in Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences: HC Wainwright 22nd Annual Investment Conference on Septembe
Read more →CRVSCorvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
BURLINGAME, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will be on Tuesday, Augu
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020
BURLINGAME, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a busines
Read more →CRVSCorvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19
Approach stimulates immune response by activating B cells to enhance antibody production Safety and scientific basis supported by ongoing cancer clinical trial Study designed to evaluate anti-viral antibody response in up to 30 COVID-19 patients with mild to moderate symptoms
Read more →CRVSCorvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant
Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders Data Includes Additional Patients with Advanced Refractory Renal Cell Cancer, Supporti
Read more →CRVSCorvus Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
BURLINGAME, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhanc
Read more →CRVSCorvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer at the ASCO20 Virtual Scientific Program
BURLINGAME, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhanc
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
BURLINGAME, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enha
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report First Quarter 2020 Financial Results on April 30, 2020
BURLINGAME, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enha
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
BURLINGAME, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enha
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2019 Financial Results on March 5, 2020
BURLINGAME, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a co
Read more →CRVSCorvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium
BURLINGAME, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, ann
Read more →CRVSCorvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum
BURLINGAME, Calif., Feb. 01, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, ann
Read more →CRVSCorvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
BURLINGAME, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, ann
Read more →CRVSCorvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production Company also presents data supporting potential of Adenosine Gene Signature to serve
Read more →CRVSImmunobiology and Clinical Activity of CPI - 006, an Anti - CD73 Antibody with Immunomodulating Properties in a Phase 1/1b Trial in Advanced Cancers Luke JJ, Merchan J, Harshman LC
Immunobiology and Clinical Activity of CPI - 006, an Anti - CD73 Antibody with Immunomodulating Properties in a Phase 1/1b Trial in Advanced Cancers Luke JJ, Merchan J, Harshman LC, Marron T, Powderly J, Barve M, LoRusso P, Johnson M, Hotson A, Gittelman R, Munneke B, Buggy J, Wi
Read more →CRVSCorvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting
BURLINGAME, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, tod
Read more →CRVSCorvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
BURLINGAME, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, tod
Read more →CRVSCorvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019
BURLINGAME, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, tod
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
BURLINGAME, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business update and reported f
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019
BURLINGAME, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a co
Read more →CRVSCorvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
BURLINGAME, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from
Read more →CRVSCorvus Pharmaceuticals to Present at the 2019 Wedbush Healthcare Conference
BURLINGAME, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the 201
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
BURLINGAME, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business update and reported f
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019
BURLINGAME, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a co
Read more →CRVSImmunobiology, Preliminary Safety and Efficacy of CPI - 006, an Anti - CD73 Antibody with Immune Modulating Activity, in a Phase 1 Trial in Advanced Cancers 1 Jason J.
Immunobiology, Preliminary Safety and Efficacy of CPI - 006, an Anti - CD73 Antibody with Immune Modulating Activity, in a Phase 1 Trial in Advanced Cancers 1 Jason J. Luke*, John D. Powderly II, Jaime R. Merchan , Minal A. Barve , Andrew N. Hotson, Mehrdad Mobasher, Long Kwei, G
Read more →CRVSCorvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting
Clinical and laboratory results support a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production Initial Results demonstrated dose-dependent disease control in patients with advanced, refractory disease when administ
Read more →CRVSCorvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
BURLINGAME, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the Jeff
Read more →CRVSCorvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
BURLINGAME, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present initial cli
Read more →CRVSCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
Announces Initiation of Enrollment in Phase 1/1b Trial of ITK inhibitor CPI-818 Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focu
Read more →CRVSCorvus Pharmaceuticals to Provide Business Update and Report First Quarter 2019 Financial Results on May 9, 2019
BURLINGAME, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a con
Read more →CRVSCorvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
BURLINGAME, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the four
Read more →CRVSCorvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
BURLINGAME, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will present
Read more →CRVSCorvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360 Conference
BURLINGAME, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation of updated bio
Read more →CRVSCorvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360 Conference
BURLINGAME, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present updated da
Read more →CRVSCorvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer
BURLINGAME, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the appointment of Linda S. Gra
Read more →CRVSCorvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
Company on track to submit Investigational New Drug application for CPI-818 in early 2019 BURLINGAME, Calif., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercializatio
Read more →CRVSCorvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist
Both CPI-006 monotherapy and CPI-006 in combination with CPI-444 trial arms now enrolling patients at U.S. sites CPI-006 in combination with CPI-444 targets multiple points in the adenosine pathway BURLINGAME, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, In
Read more →CRVSCorvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference
BURLINGAME, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present a
Read more →CRVSCorvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting
CPI-444 demonstrated prolonged survival in patients with refractory renal cell carcinoma both as a monotherapy and in combination with atezolizumab Novel adenosine gene signature biomarker associated with response to CPI-444 therapy CPI-006 early clinical data showed evidence o
Read more →CRVSCorvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018
Event will provide a review of new CPI-444 and CPI-006 data presented at SITC & ESMO BURLINGAME, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of
Read more →CRVSCorvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
BURLINGAME, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the third
Read more →CRVSCorvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress
Predictive biomarker can potentially identify patients most likely to benefit from CPI-444 and other therapies targeting the adenosine pathway BURLINGAME, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical co
Read more →CRVSCorvus Pharmaceuticals to Present Data on Lead Programs at the European Society for Medical Oncology (ESMO) 2018 Congress and the Society for Immunotherapy of Cancer (SITC) Annual Meeting
BURLINGAME, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from
Read more →CRVSCorvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies
BURLINGAME, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the publication of results of p
Read more →CRVSCorvus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
BURLINGAME, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present
Read more →CRVSCorvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
BURLINGAME, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the secon
Read more →CRVSCorvus Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
BURLINGAME, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present a
Read more →CRVSCorvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy
BURLINGAME, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced publication of results of precli
Read more →CRVSCorvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
BURLINGAME, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at
Read more →CRVSCorvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
BURLINGAME, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the first q
Read more →CRVSCorvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
BURLINGAME, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it is enrolling patients i
Read more →CRVSCorvus Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference 2018
BURLINGAME, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present a
Read more →CRVSCorvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourt
Read more →CRVSCorvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum
BURLINGAME, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced new data from an ongoing preclin
Read more →CRVSCorvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
– Clinical Data from Renal Cell Carcinoma Cohorts Presented in Oral Session at SITC 32nd Annual Meeting – – Adenosine Pathway Gene Expression Associated with Response to Therapy and Resistance to Prior Anti PD-(L)-1 – BURLINGAME, Calif., Nov. 11, 2017 (GLOBE NEWSWIRE) -- Corv
Read more →CRVSCorvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
BURLINGAME, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the third quarte
Read more →CRVSCorvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
BURLINGAME, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present data on lead chec
Read more →CRVSCorvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
BURLINGAME, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the
Read more →CRVSCorvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
BURLINGAME, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 2
Read more →CRVSCorvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the second quart
Read more →CRVSCorvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology
BURLINGAME, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will host an R&D Day on Tuesda
Read more →CRVSCorvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment
Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment -- Clinical Data from Company's Ongoing Phase 1/1b Study in Expansion Cohorts Presented in Oral Pres
Read more →CRVSCorvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting
BURLINGAME, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present an oral abstract p
Read more →CRVSCorvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program
BURLINGAME, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company, announced today that it has licensed global rights to an undisclosed novel immuno-oncology program, which includes a lead product candidate
Read more →CRVSCorvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the first quarter
Read more →CRVSCorvus Pharmaceuticals Expands CPI-444 Clinical Collaboration with Genentech
CPI-444 in Combination with Atezolizumab Will Advance into Phase 1b/2 Study in Patients with Non-Small Cell Lung Cancer who are Resistant/Refractory to Prior Anti-PD(L)-1 Treatment as Part of MORPHEUS, Genentech’s Novel Cancer Immunotherapy Development Platform BURLINGAME, Calif
Read more →CRVSCorvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced Cancers
– Clinical Data Presented in Oral Plenary Session at American Association for Cancer Research (AACR) Annual Meeting 2017 – – Data Supports Expansion of Three Additional Cohorts in Non-small Cell Lung Cancer Treated with Single Agent CPI-444, Renal Cell Cancer and Non-small Cell
Read more →CRVSCorvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017
BURLINGAME, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present interim data fro
Read more →CRVSCorvus Pharmaceuticals to Reschedule R&D Day Due to Severe Winter Storm in the New York Tri-State Area
BURLINGAME, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced that the company will postpone its R&D Day s
Read more →CRVSCorvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
BURLINGAME, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the fourth quar
Read more →CRVSCorvus Pharmaceuticals to Host R&D Day Highlighting the Role of the Adenosine Pathway in Immuno-Oncology
BURLINGAME, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will host and provid
Read more →CRVSCorvus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference 2017
BURLINGAME, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the C
Read more →CRVSCorvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444
-- Cohort Reached Protocol-Predefined Criteria for Expansion Based on Responses to Single-Agent Treatment -- BURLINGAME, Calif., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development a
Read more →CRVSCorvus Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017
BURLINGAME, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 3
Read more →CRVSCorvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors
BURLINGAME, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS) today announced the appointment of Ian T. Clark, former chief executive officer and head of North American Commercial Operations at Genentech, Inc., to its Board of Directors. "Ian i
Read more →CRVSCorvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data with Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety and Evidence of Anti-Tumor Activity as a Single Agent in Patients with Advanced Refractory
Corvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data with Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety and Evidence of Anti-Tumor Activity as a Single Agent in Patients with Advanced Refractory Cancers Biomarker Data Also Presented Indicating Evidence
Read more →CRVSCorvus Pharmaceuticals Announces Third Quarter Financial Results and Provides Business Update Burlingame, Calif.
Corvus Pharmaceuticals Announces Third Quarter Financial Results and Provides Business Update Burlingame, Calif., November 3, 2016 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel i
Read more →CRVSCorvus Pharmaceuticals to Present at SITC’s 31st Annual Meeting
BURLINGAME, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it will present preliminary clinical a
Read more →CRVSCorvus Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference
BURLINGAME, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that management will present at the Cr
Read more →CRVSCorvus Pharmaceuticals Announces Biomarker Findings from Phase 1/1b Study of Lead Oral Checkpoint Inhibitor CPI-444 Presented at ESMO 2016 Congress - Company Completes Enrollment in Dose-Selection Part of Clinical Trial
Corvus Pharmaceuticals Announces Biomarker Findings from Phase 1/1b Study of Lead Oral Checkpoint Inhibitor CPI-444 Presented at ESMO 2016 Congress - Company Completes Enrollment in Dose-Selection Part of Clinical Trial Burlingame, Calif., October 10, 2016 Corvus Pharmaceutic
Read more →CRVSCorvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at ESMO 2016 Congress
BURLINGAME, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present preclinical data
Read more →CRVSCorvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Preclini
Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Preclinical Studies Demonstrate Activity of CPI-444 Both Alone a
Read more →CRVSCorvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
BURLINGAME, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present preclinical data
Read more →CRVSCorvus Pharmaceuticals Announces Second Quarter Financial Results and Provides Business Update Burlingame, Calif.
Corvus Pharmaceuticals Announces Second Quarter Financial Results and Provides Business Update Burlingame, Calif., August 4, 2016 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), today announced financial results for the second quarter and six months ended June 30, 2016 and provide
Read more →CRVSCorvus Pharmaceuticals Announces Second Quarter Financial Results and Provides Business Update
BURLINGAME, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), today announced financial results for the second quarter and six months ended June 30, 2016 and provided a business update. “We are making good progress with our product candidates,
Read more →CRVSCorvus Pharmaceuticals to Present at Cantor Fitzgerald’s Second Annual Healthcare Conference on July 12
BURLINGAME, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced management will present at the Cantor
Read more →CRVSCorvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
BURLINGAME, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it has named former Roche/Genentech Vi
Read more →CRVSCorvus Pharmaceuticals’ Ian McCaffery, PhD to Present at Rational Combinations 360 June 23-24, New York
BURLINGAME, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced Corvus’s Dr. Ian McCaffery will presen
Read more →CRVSCorvus Pharmaceuticals Announces First Quarter 2016 Financial Results
BURLINGAME, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the three months
Read more →CRVSCorvus Pharmaceuticals Announces First Quarter 2016 Financial Results Burlingame, Calif.
Corvus Pharmaceuticals Announces First Quarter 2016 Financial Results Burlingame, Calif., May 5, 2016 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, toda
Read more →CRVSCorvus Pharmaceuticals Announces Results of Preclinical Studies Demonstrating Enhanced Immune Responses and Anti-Tumor Activity with CPI-444, an Investigational Immuno-Oncology Therapy Data from Stu
Corvus Pharmaceuticals Announces Results of Preclinical Studies Demonstrating Enhanced Immune Responses and Anti-Tumor Activity with CPI-444, an Investigational Immuno-Oncology Therapy Data from Studies of Novel Checkpoint Inhibitor Presented in Oral and Poster Presentation Ses
Read more →CRVSCorvus Pharmaceuticals Announces Results of Preclinical Studies Demonstrating Enhanced Immune Responses and Anti-Tumor Activity with CPI-444, an Investigational Immuno-Oncology Therapy
BURLINGAME, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced results of three preclinical studies
Read more →CRVSCorvus Pharmaceuticals to Present at AACR Annual Meeting April 16 – 20 in New Orleans
BURLINGAME, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced oral and poster presentations of key
Read more →CRVSCorvus Announces Pricing of Initial Public Offering
BURLINGAME, Calif., March 22, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced the pricing of its initial public off
Read more →Competitive Position
How CRVS ranks across every disease it competes inCompetitive Position is a premium feature
See how CRVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial